C12N 2501/60
Transcription factors
C12N2501/60 (Transcription factors) appears on 814 US grants and 1,637 published applications in this corpus.
Search patents in C12N- Granted patents
- 814
- Published applications
- 1,637
- Assignees
- 640
- Inventors
- 2,512
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 10 |
| 2003 | 0 | 10 |
| 2004 | 3 | 17 |
| 2005 | 10 | 15 |
| 2006 | 3 | 18 |
| 2007 | 1 | 16 |
| 2008 | 6 | 15 |
| 2009 | 5 | 27 |
| 2010 | 9 | 54 |
| 2011 | 14 | 77 |
| 2012 | 18 | 85 |
| 2013 | 23 | 88 |
| 2014 | 31 | 74 |
| 2015 | 62 | 80 |
| 2016 | 58 | 83 |
| 2017 | 61 | 105 |
| 2018 | 61 | 106 |
| 2019 | 61 | 99 |
| 2020 | 64 | 99 |
| 2021 | 60 | 108 |
| 2022 | 56 | 119 |
| 2023 | 40 | 85 |
| 2024 | 59 | 99 |
| 2025 | 48 | 99 |
| 2026 | 54 | 48 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Composition for enhancing reprogramming efficiency from somatic cell to induced pluripotent stem cell, comprising mTOR activator, and method for enhancing reprogramming efficiency by using same6 Oct 2026US 12,753,394 B2Korea University Research and Business Foundation
- Self-inactivating lentiviral vector comprising a FoxP3 expression cassette29 Sep 2026US 12,747,454 B2The Board of Trustees of the Leland Stanford Junior University
- Production method for microglia22 Sep 2026US 12,742,151 B2Elixirgen Scientific, Inc.
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Method for producing astrocyte-like cells15 Sep 2026US 12,735,677 B2Jsr Corporation
- Application of stem cells or transgenic stem cells8 Oct 2026US 2026/0306716 A1Anhui Longhui Stem Cell Biotechnology Co., Ltd
- T cell progenitor production method1 Oct 2026US 2026/0297522 A1Kyoto University
- Oct3/4 protein variants, and method for producing induced pluripotent stem cells1 Oct 2026US 2026/0297535 A1Riken
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Synthetic notch receptors for use in customized spatial control of multiple gene expressions and uses thereof1 Oct 2026US 2026/0297539 A1The Regents of the University of California
Most cited
By later US patents
- Human pancreatic epithelial progenitor cells and methods of isolation and use thereof171US 6,436,704 B1Raven Biotechnologies, Inc. · 2002
- Nuclear reprogramming factor151US 8,048,999 B2Kyoto University · 2011
- Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells126US 9,850,499 B2Loma Linda University · 2017
- Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells125US 8,058,065 B2Kyoto University · 2011
- Compositions and methods for reprogramming eukaryotic cells103US 8,808,982 B2Cellscript, LLC · 2014